Xconomy’s Digital Events →
Tioma Therapeutics has a portfolio of anti-CD47 antibodies, which create an immune response to cancer cells. Photo courtesy Tioma: https://www.tiomatherapeutics.com/science/cd47-biology/
Sponsored · Video
A Fireside Chat with Medpace's Regulatory Affairs Director David Horton
Sponsored · Whitepaper
Knowing the volume of procedures and growth trends by site of care can allow you to understand the market demand for your product
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
© 2007-2021, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.